Methyldopa‐induced systemic lupus erythematosus

David M. Nordstrom, Sterling G. West, Robert L. Rubin
In: Arthritis & Rheumatism · 1989 · vol. 32(2) , pp. 205–208 · doi:10.1002/anr.1780320214 · PMID:2645875 · W2149285764
article OA: closed CC0
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by qwen3.7-flash, 2026-10-02 ⓘ

This case report describes a patient who developed methyldopa-induced systemic lupus erythematosus characterized by hemolytic anemia and arthritis, with symptoms resolving after drug withdrawal.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Thirteen months after starting methyldopa therapy, a 55-year-old white male patient presented with a syndrome of hemolytic anemia, arthritis, photosensitivity, and a positive antinuclear antibody test result. Methyldopa-induced antinuclear antibodies were mainly IgG, directed against class H1 histones. Antibodies to native DNA and nonhistone proteins were not detected. Upon withdrawal of methyldopa therapy, and with a short course of prednisone and danazol therapy, the patient's symptoms and hemolytic anemia resolved. His clinical symptoms and serologic abnormalities returned to normal and remained negative after 2 years of followup.

My notes (saved in your browser only)

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

References (17)

Source provenance

openalex
last seen: 2026-05-11T06:00:05.006021+00:00
unpaywall
last seen: 2026-10-08T06:33:43.470499+00:00
License: CC0 · commercial use OK